Working… Menu

Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01125046
Recruitment Status : Active, not recruiting
First Posted : May 18, 2010
Last Update Posted : April 12, 2018
Information provided by (Responsible Party):
Northwestern University

Brief Summary:

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.

PURPOSE: This phase II trial is studying how well bevacizumab works in treating patients with recurrent or progression meningiomas.

Condition or disease Intervention/treatment Phase
Acoustic Schwannoma Adult Anaplastic Meningioma Adult Ependymoma Adult Grade I Meningioma Adult Grade II Meningioma Adult Meningeal Hemangiopericytoma Adult Papillary Meningioma Neurofibromatosis Type 1 Neurofibromatosis Type 2 Recurrent Adult Brain Tumor Biological: bevacizumab Phase 2

Detailed Description:


I. To determine the efficacy of bevacizumab in patients with recurrent or progressive benign and atypical/malignant meningiomas, despite prior therapy, as measured by six-month progression-free survival.


I. To describe the response rate and overall-survival in this patient population.

II. To evaluate the safety profile of bevacizumab in patients with recurrent meningiomas.

III. To perform an exploratory study in patients with hemangioblastoma and hemangiopericytoma.

IV. To assess tissue for VEGF and VEGFR to correlate with response. An exploratory analysis of HER-2 will be performed.


Patients receive bevacizumab IV over 30-90 minutes every 2 weeks for 6 months. Patients may then receive bevacizumab IV every 3 weeks for up to 12 months. Treatment continues in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed every 3 months for 2 years.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Trial of Bevacizumab in Patients With Recurrent or Progressive Meningiomas
Study Start Date : July 2010
Estimated Primary Completion Date : July 2019
Estimated Study Completion Date : July 2020

Arm Intervention/treatment
Experimental: Arm I
Patients receive bevacizumab IV over 30-90 minutes every 2 weeks for 6 months. Patients may then receive bevacizumab IV every 3 weeks for up to 12 months. Treatment continues in the absence of disease progression or unacceptable toxicity.
Biological: bevacizumab
Given IV
Other Names:
  • anti-VEGF humanized monoclonal antibody
  • anti-VEGF monoclonal antibody
  • anti-VEGF rhuMAb
  • Avastin
  • recombinant humanized anti-VEGF monoclonal antibody
  • rhuMAb VEGF

Primary Outcome Measures :
  1. Progression free survival [ Time Frame: At 6 months ]

Secondary Outcome Measures :
  1. Response rate and overall-survival [ Time Frame: During week 8, every 8 weeks thereafter while on treatment and intermittently during followup ]
    Patients will have scans during week 8 and every 8 weeks thereafter while on treatment to assess response. Survival status will be confirmed intermittently during followup.

  2. Safety profile of bevacizumab [ Time Frame: Every 2 weeks while on treatment up to 28 days after the last dose ]
    Adverse events will be assessed every 2 weeks while on treatment up to 28 days after the last dose.

  3. Levels of VEGF and VEGFR expression in tumor tissue as compared to response rate [ Time Frame: At baseline and every 8 weeks until disease progression or death ]
    Tissue will be collected for the VEGF and VEGFR correlative studies during the screening phase. Patients will undergo radiological assessments every 8 weeks during treatment to determine disease status. The level of VEGF and VEGFR expression will be compared with the response rate as determined at the time of disease progression or death.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically proven recurrent or progressive intracranial meningioma; this includes benign, atypical, or malignant meningioma who may or may not have neurofibromatosis type 1 or 2; pathology can be from initial surgery; OR histologically proven intracranial hemangiopericytoma, hemangioblastoma (with or without metastatic disease), acoustic neuroma, or intracranial schwannoma
  • Unequivocal evidence for tumor progression by MRI (or CT scan if MRI is contraindicated); the scan must be performed within 14 days of registration
  • Steroid dosing- must be on stable dose for at least 5 days prior to baseline imaging (Steroids are not required at the time of baseline imaging)
  • Recent resection for recurrent tumor - patients will be eligible as long as they are greater than four weeks from surgery, have recovered from the effects of surgery, and have residual disease that can be evaluated; to best assess the extent of residual disease post-operatively, a CT/MRI should be done no later than 96 hours in the immediate post-operative period or at least 4 weeks post-operatively; if the 96 hour scan is more than 14 days before registration, it should be repeated
  • Prior radiation therapy - patients may have been treated with standard external beam radiation or radiosurgery in any combination; an interval of >= 8 weeks (56 days) must have elapsed from the completion of radiation therapy to study entry and there must be subsequent evidence of tumor progression
  • Patients with prior stereotactic radiosurgery must have confirmation of true progressive disease rather than radiation necrosis based on PET, MR spectroscopy or surgical documentation of disease
  • Prior therapy: there is no limitation on the number of prior surgeries, radiation therapy, radiosurgery treatments, or chemotherapy agents
  • Prior surgery: must be > 4 weeks from surgery
  • Prior radiation: must be 8 weeks from end of treatment
  • Prior chemotherapy: must be at least 4 weeks from cytotoxic therapy and 2 weeks from biologic therapies
  • All patients must sign an informed consent indicating that they are aware of the investigational nature of the study
  • Patients must sign an authorization for the release of their protected health information
  • Karnofsky performance status >= 60%
  • Absolute neutrophil count (ANC) >= 1,000/mm^3
  • Platelets >= 100,000/mm^3
  • Hemoglobin >= 8gm/dl
  • Serum aspartate transaminase (AST; serum glutamic oxaloacetic transaminase [SGOT]) =< 2.5 x local laboratory upper limit of normal (ULN)
  • Serum alanine transaminase (ALT; serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x local laboratory upper limit of normal (ULN)
  • Creatinine =< 2.0 mg/dl
  • PT, INR, and PTT =< 1.5 times institutional upper limits of normal
  • Total serum bilirubin =< 1.5
  • Patients with a history of NF may have other stable CNS tumors, such as schwannoma, acoustic neuroma, or ependymoma, but ONLY if these lesions have been stable in size for the preceding 6 months
  • No history of any other cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix) unless in complete remission and off all therapy for the disease for a minimum of 5 years
  • Patients may not have a history of prior treatment with inhibitors of the VEGF pathway (eg: VEGF trap, cediranib, vatalanib, sunitinib, sorafenib, etc.)
  • No concurrent treatment on another clinical trial; supportive care trials or non-treatment trials, e.g. QOL, are allowed
  • No history of known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness or other active infection
  • Anticoagulation with therapeutic warfarin (INR <3) and low molecular weight heparin is allowed
  • Pregnancy or breast-feeding (Patients must be surgically sterile, postmenopausal, or agree to use effective contraception during the period of therapy; the definition of effective contraception will be based on the judgment of the principal investigator or a designated associate)
  • Male patients must be surgically sterile or agree to use effective contraception; women of childbearing potential must have a negative B-HCG pregnancy test documented within 14 days prior to registration
  • Patient must be able to comply with the study and follow-up procedures
  • Life expectancy greater than 12 weeks
  • Adequately controlled hypertension (defined as systolic blood pressure =< 150 mmHg and/or diastolic blood pressure =< 100 mmHg)
  • No history of hypertensive crisis or hypertensive encephalopathy
  • Patients must not have New York Heart Association (NYHA) Grade II or greater congestive heart failure
  • No history of myocardial infarction or unstable angina within 12 months prior to Day 1 of treatment
  • No history of stroke or transient ischemic attack
  • Patients must not have significant vascular disease (e.g., aortic aneurysm, requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to Day 1 of treatment
  • No history of hemoptysis (>= 1/2 teaspoon of bright red blood per episode) within 1 month prior to Day 1 of treatment
  • No evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
  • No history of major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1 of treatment or anticipation of need for major surgical procedure during the course of the study
  • No history of minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to Day 1 of treatment
  • No history of abdominal fistula or gastrointestinal perforation within 6 months prior to Day 1 of treatment
  • Patients must not have serious non-healing wound, active ulcer, or unhealed bone fracture
  • Urine protein:creatinine (UPC) ratio =< 1.0 at screening OR urine dipstick for proteinuria < 2 (patients discovered to have >= 2 proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate =< 1g of protein in 24 hours to be eligible)
  • No known hypersensitivity to any component of bevacizumab
  • Patients may not have a prior history of bowel perforation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01125046

Layout table for location information
United States, Illinois
Northwestern University
Chicago, Illinois, United States, 60611
United States, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02215
United States, New York
Columbia University Medical Center
New York, New York, United States, 10032
United States, Virginia
University of Virginia
Charlottesville, Virginia, United States, 22903
United States, Washington
University of Washington
Seattle, Washington, United States, 98109-1023
Sponsors and Collaborators
Northwestern University
Layout table for investigator information
Principal Investigator: Priya Kumthekar, MD Northwestern University

Layout table for additonal information
Responsible Party: Northwestern University Identifier: NCT01125046     History of Changes
Other Study ID Numbers: NU 09C2
STU00024715 ( Other Identifier: Northwestern University IRB )
First Posted: May 18, 2010    Key Record Dates
Last Update Posted: April 12, 2018
Last Verified: April 2018
Additional relevant MeSH terms:
Layout table for MeSH terms
Neurofibromatosis 2
Neurofibromatosis 1
Neuroma, Acoustic
Central Nervous System Neoplasms
Nervous System Neoplasms
Neoplasms by Site
Nervous System Diseases
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms, Vascular Tissue
Meningeal Neoplasms
Nerve Sheath Neoplasms
Neoplastic Syndromes, Hereditary
Neurocutaneous Syndromes
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Genetic Diseases, Inborn
Peripheral Nervous System Diseases